IL Therapeutics, a U of S spin-off company located at Innovation Place, today received $3 million from the Western Life Sciences Venture Fund (WLS) to back research and development of a new drug treatment for Acute Respiratory Distress Syndrome (ARDS).

MCN Bioproducts Inc., the brainchild of University of Saskatchewan researchers David Maenz, Henry Classen and Rex Newkirk, has been named winner of the third annual Innovation Place-Industry Liaison Office Award of Innovation.

A letter of intent to commercialize a new drug treatment for Acute Respiratory Distress Syndrome (ARDS) has been signed between the University of Saskatchewan’s Industry Liaison Office (ILO) and IL Therapeutics Inc., a new start-up firm at Innovation Place on the U of S campus.

Seven University of Saskatchewan researchers whose work advances needle-free drug delivery, emergency stroke treatment and added value for canola were nominated for the third annual Innovation Place-Industry Liaison Office “Award of Innovation.”